Editas Medicine, Inc. (EDIT)

NMS – Real vaqt narxi. Valyuta: USD

2.85

-0.10 (-3.39%)

Yopilishda: Aug 12, 2026, 3:59 PM EDT

2.92

+0.08 (2.76%)

Bozordan keyin: Aug 12, 2026, 4:18 PM EDT

10.08.2026

Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?

Here is how Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.

06.08.2026

EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus

Editas beats Q2 estimates as collaboration revenues surge, while EDIT-401 advanced toward clinical testing with encouraging preclinical data.

05.08.2026

Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates

Editas Medicine (EDIT) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.63 per share a year ago.

04.08.2026

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D.

Recognized leader in cardiovascular medicine and human genetics brings extensive experience spanning scientific innovation, therapeutic discovery, and clinical leadership as Editas advances EDIT-401 to the clinic Recognized leader in cardiovascular medicine and human genetics brings extensive experience spanning scientific innovation, therapeutic discovery, and clinical leadership as Editas advances EDIT-401 to the clinic

Videolar

No Data

There is no data to display

Press-relizlar

04.08.2026

Editas Medicine, Inc. (EDIT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Editas Medicine, Inc. (EDIT)

Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?

EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus

Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D.

Videolar

No Data

Press-relizlar

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D.

Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?

EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus

Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D.

Videolar

No Data

Press-relizlar

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D.

Search stocks

Editas Medicine, Inc. (EDIT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Editas Medicine, Inc. (EDIT)

Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?

EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus

Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D.

Videolar

No Data

Press-relizlar

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D.

Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?

EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus

Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D.

Videolar

No Data

Press-relizlar

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D.